Elanco Animal Health Incorporated $ELAN Shares Purchased by Bowen Hanes & Co. Inc.

Bowen Hanes & Co. Inc. lifted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 11.0% in the fourth quarter, Holdings Channel reports. The firm owned 2,623,770 shares of the company’s stock after acquiring an additional 259,000 shares during the period. Bowen Hanes & Co. Inc.’s holdings in Elanco Animal Health were worth $59,376,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Elanco Animal Health by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock valued at $978,536,000 after purchasing an additional 759,623 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Elanco Animal Health by 8.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock valued at $497,610,000 after purchasing an additional 1,962,276 shares during the period. UBS Group AG lifted its position in Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after acquiring an additional 5,961,457 shares during the period. Geode Capital Management LLC lifted its position in Elanco Animal Health by 7.3% during the 4th quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock worth $213,343,000 after acquiring an additional 640,098 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Leerink Partners increased their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. KeyCorp increased their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Morgan Stanley raised their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Finally, UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.20.

Elanco Animal Health Trading Up 4.0%

Shares of ELAN opened at $24.57 on Thursday. The stock’s 50-day moving average is $22.92 and its two-hundred day moving average is $23.36. The stock has a market cap of $12.27 billion, a PE ratio of -49.14, a P/E/G ratio of 2.54 and a beta of 1.69. Elanco Animal Health Incorporated has a 12 month low of $13.15 and a 12 month high of $27.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by corporate insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.